BGI News More Academic and Education More Research Collaboration More BGI in the news More
Contact Us

Media Contact

Tel: +86-755-36307212

BGI Signs MoU with Xing Technologies in Australia
Publish Date: 2018-08-23

On August 22, BGI, the world’s leading genomics organization, signed a Memorandum of Understanding (MoU) with Xing Technologies Pty Ltd ((hereafter referred to as XING), a spin-off company from University of Queensland, focusing on translating diagnostic technologies. The two sides are intended to apply their advantages on collaborative research and innovation of cutting-edge life sciences technology towards personalized healthcare. Within the frame of the MoU, both parties pledge to establish bilateral cooperation covering in the following areas:

  • DNB technology: optimize current DNA nanoball technology to improve sequencing data quality and throughput resulting in reduced sequencing costs;
  • Circulating Tumour/Stem Cells (CTC) technology (cells shed from a primary tumor that disseminate in the body’s circulatory system): integrate CTC isolation, characterization and sequencing for fast and accurate disease screening and monitoring;
  • Point-of-care product: based on XING’s patented “Laboratory in a Drop” technology, undertake joint research into, and manufacturing of a transformative diagnostic product developed by XING to offer the world, including millions of Australians, an accurate, rapid and inexpensive point-of-care disease screening, diagnosis and monitoring kit. The applications even extend to human health as well as animals and plant material, such as agriculture, aquaculture, veterinary science.

Dr. Paul Mainwaring, Chief Medical Officer of XING, expressed his delight and optimism in respect of the collaboration with BGI. “BGI and XING share a common vision to dramatically improve health outcomes for people around the world. Our partnership promises to leverage technology and deliver scale to truly transform the health sector. We are honuored to be working in close relationship with BGI, a global leader in genomics.”, said Dr. Mainwaring.

Mr. Duncan YU, BGI’s Executive Vice President and MGI’s President said, “We are very excited about the collaboration. The joint effort of expertise in nanotechnology and genomics will lead to innovations in delivering better health solution. We are looking forward to making point-of-care products available for the global users.”

As part of the collaboration, MGI, a subsidiary corporation of BGI manufacturing proprietary sequencers and related instrumentation, has deployed its BGISEQ-500 NGS sequencer at XING’s laboratory in Brisbane.

Since the BGI Australia office opened in 2016, BGI has initiated projects covering a wide range of areas via partnerships with strong local scientific research partners, such as imaging and genomics cancer, infectious disease, marine biology, and biodiversity. For more information on BGI Australia please visit here.
About Xing Technologies
Xing Technologies is a spin-out company specializing in world-leading disease diagnosis and monitoring technologies, including cancer. Its proprietary nanotechnologies are transforming the future practice of medicine and healthcare. These include nanotechnologies for nucleic acid, protein and rare cell detection. The company has concluded a Series A investment round, successful deals with national and international companies and is currently growing its operations.
About MGI
MGI Tech Co. Ltd. (MGI), a subsidiary of BGI the largest genomics organization in the world, is specialized in R&D and manufacturing of proprietary instrumentation, medical devices, ancillary consumables and biological reagents e.g. genetic sequencers, mass spectrometers, medical imaging systems, and comprehensive solutions for life science research and applications. MGI owns more than 100 patents. Headquartered in China, MGI has established local technical support teams in Australia, Europe, Americas, and South-east Asia. With the vision to “enable effective and affordable healthcare solutions for all”, MGI has more than 500 employees worldwide and strives to be a leading innovator in life science technologies.